Please provide your email address to receive an email when new articles are posted on . Although lenabasum failed to meet its efficacy endpoint in a trial of patients with diffuse cutaneous systemic ...

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

Patients who underwent autologous stem cell transplantation (ASCT) for diffuse cutaneous systemic sclerosis (dcSSc), also known as scleroderma, did no better than others receiving conventional ...

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

Systemic sclerosis (SSc), also referred to as scleroderma, is a rare autoimmune disease associated with vasculopathy, inflammation, and fibrosis of the skin and/or internal organs. Interstitial lung ...

Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...